October 28, 2016
8:00 – 9:00 am
6 Founders Conference Room
Adam Bagg, MD
Target Audience
This program has been designed for physicians, fellows, residents, medical students, and medical technicians in the medical specialties of internal medicine, hematology/oncology, and pathology.
Series Educational Objectives
After completing this activity, participants should be able to:
- Identify basis concepts and controversies in hematopathology and allied fields (hematology/oncology, flow cytometry, molecular diagnostics, cytogenetics) and apply recently published data to these cases
- Identify inappropriately diagnosed hematologic malignancies and employ emerging diagnostic recommendations to improve standard-of-care
- Integrate emerging diagnostic testing modalities in hematopathology
- Employ effective multidisciplinary collaboration to improve patient care
Accreditation
Physicians: The Perelman School of Medicine at the University of Pennsylvania is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Designation of Credit
Physicians: The Perelman School of Medicine at the University of Pennsylvania designates this live activity for a maximum of 1 AMA PRA Category 1 Credit ™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Approved for (PSRM) patient safety/risk management designation
Acknowledgement of Commercial Support* NONE
For more information, please contact
Alexa Koike
215-614-0978
Disclosure of Relevant Financial Relationships and Unapproved Uses of Products
It is policy at the Perelman School of Medicine at the University of Pennsylvania and the Hospital of the University of Pennsylvania, Department of Nursing Education, Innovation and Professional Developmentfor individuals who are in a position to control the content of an educational activity to disclose to the learners all relevant financial relationships that they have with any commercial interest that provide products or services that may be relevant to the content of this continuing education activity. For this purpose we consider relationships of the person involved to include financial relationships of a spouse or partner.
The intent of this policy is to ensure that Penn CME/CNE certified activities promote quality and safety, are effective in improving medical practice, are based on valid content, and are independent of control from commercial interests and free of commercial bias. Peer review of all content was conducted for all faculty presentations whose disclosure information was found to contain relationships that created a conflict of interest relevant to the topic of their presentation. In addition, all faculty were instructed to provide balanced, scientifically rigorous and evidence-based presentations.
The staff in the Office of CME at the Perelman School of Medicine at the University of Pennsylvania, Mila Kostic, CHCP, FACEHP, Director of CME,Zalman Agus, MD,Senior peer reviewerand Patricia A. Smith, DNP, RN-BC,Nursing professional development specialist of the HUP Department of Nursing Innovation and Development have disclosed that they have norelevant financial relationships with any commercial interests related to the content of this educational activity.
The following individuals have disclosed that they have no relevant financial relationships with any commercial interests related to the content of this educational activity:
Planning Committee & Presenter Name
Dale Frank, MD / Megan Lim, MD, PhD / Adam Bagg, MD / AgataBogusz, MD, PhDRachel Sargent, MD / Mariusz Wasik, MD / Michele Paessler, DO / Vinodh Pillai, MBBS, PhD
Gerald Wertheim, MD, PhD
Presenter Name
John Astle MD, PHD / Siddharth Bhattacharyya, MD / Kyle Devins, MD / KojoElenitoba-Johnson, MDPaul Hess, MD / Taylor Jenkins, MD / Daniel Landsburg, MD / Jie Li, MD
Elliot LHospital, MD / Yang Li, MD, PhD / Sophia Ma, MD / Alexander Macnow, MD
Anders Meyer, MD / M. Reza Nejati, MD / Sharon Song, MD / Kevin Trowell, MD
The following individuals have reported the listed relevant financial relationships with commercial interests related to the content of this educational activity.
Presenter NameName of Commercial InterestRelationship
David Fajgenbaum, MBA, MScJanssen PharmaceuticalsGrant/Research
Alain Rook, MDGaldermaLicensed Pending Patent
Martin Carroll, MDIncyte PharmaceuticalsSpeaker/Investigator
Astellas PharmaceuticalsInvestigator
JanssenAdvisory Panel
Relevant financial relationships are those relationships in which the individual benefits by receiving a salary, royalty, intellectual property rights, consulting fee, honoraria, ownership interest (e.g., stocks, stock options or other ownership interest, excluding diversified mutual funds), or other financial benefit. Financial benefits are usually associated with roles such as employment, management position, independent contractor (including contracted research), consulting, speaking and teaching, membership on advisory committees or review panels, board membership, and other activities from which remuneration is received or expected
Disclosure of Unapproved Uses of Products
Presenter nameProductInvestigational and/or Off-label Use
David Fajgenbaum, MBA, MScTocilizumab, Rifuximab, AnakinraTreatment Option for Off label use
Alain Rook, MDResiquimodClinical Trial Use